Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Combination With FOLFOX and Regorafenib in HER2-Negative Metastatic Esophagogastric Cancer
NCT04757363Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2021
- Primary completion
- Feb 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, regorafenib in Esophagogastric Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Started Feb 2021; status: active, not recruiting.
02
Drugs
nivolumabregorafenib
03
Conditions
Esophagogastric Cancer
Beyond the preview
Go deeper on NCT04757363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04757363.